3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Thrombocytopenia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Anemia
1
Interventions
Azacitidine
66
venetoclax
21
Decitabine
16
Cytarabine
12
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
7
fludarabine
6
pevonedistat
5
mocetinostat
5
ON 01910
5
Busulfan
5
treosulfan
4
sabatolimab
4
ruxolitinib
4
cedazuridine
4
cc-486
4
Mycophenolic Acid
4
Lenalidomide
4
Injections
4
plerixafor
3
luspatercept
3
imetelstat
3
glasdegib
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Methotrexate
3
GRN163L peptide
3
Clofarabine
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myelodysplastic Syndromes
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled